Skip to main content
Clinical Trials/NCT01651676
NCT01651676
Completed
Not Applicable

Evaluation of the VQ11 Auto-questionnaire of Quality of Life in Pneumology Investigation, During the Implementation of a Long-acting Bronchodilator Treatment of Patients With COPD.

Centre Hospitalier Universitaire, Amiens15 sites in 1 country57 target enrollmentFebruary 1, 2013
ConditionsCOPD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COPD
Sponsor
Centre Hospitalier Universitaire, Amiens
Enrollment
57
Locations
15
Primary Endpoint
VQ11 score
Status
Completed
Last Updated
5 months ago

Overview

Brief Summary

The purpose of this study is to estimate the capacity of the auto-questionnaire of quality of life, VQ11, to follow the evolution of patients with COPD (Chronic obstructive pulmonary disease) in stable state (without exacerbation in the previous 6 weeks) (3 months +/-15 days) during the implementation of a LABD (Long-acting bronchodilator) treatment.

The main objective is to compare the total Score of the VQ11 auto-questionnaire before and after LABD. A decrease of 5 points of the total score mimicking an improvement in the quality of life linked to health, specifically in the COPD.

Detailed Description

Evaluation of the VQ11 auto-questionnaire of quality of life in pneumology investigation, during the implementation of a long-acting bronchodilator treatment of patients with COPD. Two visits per patient are planned: V1: After complete information and collection of the written consent, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, 2 visual analogical scales concerning the dyspnoea and the physical activity, the short IPAQ version and the respiratory questionnaire of the Saint Georges hospital. RFE (respiratory functional exploration) is also realized during this medical exam. V2 (3 months after the treatment setup, at day90 ± 15): the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, 2 visual analogical scales and Likert scales concerning the dyspnoea and the physical activity, the short IPAQ version and the respiratory questionnaire of the Saint Georges hospital. RFE (respiratory functional exploration) is also realized during this medical exam. Inclusion period : 6 months; Study participation period / patient : 3 months; Complete study duration : 9 months

Registry
clinicaltrials.gov
Start Date
February 1, 2013
End Date
December 1, 2015
Last Updated
5 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • COPD patient with stage II, III ou IV justifying a LABD
  • Patient in stable state (without exacerbation in the previous 6 weeks)
  • Clinical criteria: dyspnoea stage I ou more (MMRC scale)
  • Adult over 18 years old.
  • Patients naïve from LABD treatment.

Exclusion Criteria

  • Other associated pathology (bronchiectasia...)
  • Heart disorder with a prevailing role in the dyspnoea
  • Cardiac decompensation in the previous year
  • Pregnancy and lactating
  • Women in genital activity without efficient contraception method (IUD or estrogen-progestin pill)
  • Lack of social insurance
  • Patient non compliant to protocol, at the investigator's appreciation
  • Simultaneous participation to other clinical trial.
  • adult under judicial protection (tutor or curator).

Outcomes

Primary Outcomes

VQ11 score

Time Frame: V1 (at baseline), V2 (3 months after V1)

To compare changes of total Score of the VQ11 auto-questionnaire before and after LABD (decrease of 5 points of the total score mimicking an improvement in the quality of life linked to health, specifically in the COPD).

Secondary Outcomes

  • RFE(V1 (at baseline), V2 (3 months after V1))
  • VQ11 and visual analogical scale regarding daily activity(V1 (at baseline), V2 (3 months after V1))
  • Likert scales(V2 (3 months after V1))
  • Saint George's Respiratory Questionnaire(V1 (at baseline), V2 (3 months after V1))
  • VQ11 sub-scores(V1 (at baseline), V2 (3 months after V1))
  • Bi-directional visual analogical scale regarding dyspnoea(V2 (3 months after V1))
  • Bi-directional visual analogical scale regarding daily activity(V2 (3 months after V1))
  • VQ11 and visual analogical scales regarding dyspnoea(V1 (at baseline), V2 (3 months after V1))
  • Dyspnoea evolution assessed by mMRC(V1 (at baseline), V2 (3 months after V1))

Study Sites (15)

Loading locations...

Similar Trials